1.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022;40(11):1358-1373.e8. doi:10.1016/j.ccell.2022.10.017.
1.
Sundberg TB, Xavier RJ, Schreiber SL, Shamji AF. Small-molecule control of cytokine function: new opportunities for treating immune disorders. Curr Opin Chem Biol. 2014;23:23-30. doi:10.1016/j.cbpa.2014.08.013.
1.
Shaw SY, Tran K, Castoreno AB, et al. Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol. 2013;8(12):2724-33. doi:10.1021/cb400352d.
1.
Bargiela D, Bianchi MT, Westover B, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017;88(7):677-684. doi:10.1212/WNL.0000000000003612.
1.
Freitas CG, Lima SMF, Freire MS, et al. An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.02518-16.
1.
Piantadosi A, Kanjilal S, Ganesh V, et al. Rapid Detection of Powassan Virus in a Patient With Encephalitis by Metagenomic Sequencing. Clin Infect Dis. 2018;66(5):789-792. doi:10.1093/cid/cix792.
1.
Lin J-R, Izar B, Wang S, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018;7. doi:10.7554/eLife.31657.
1.
Steinebach C, Lindner S, Udeshi ND, et al. Homo-PROTACs for the Chemical Knockdown of Cereblon. ACS Chem Biol. 2018;13(9):2771-2782. doi:10.1021/acschembio.8b00693.
1.
Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function. Cell Host Microbe. 2017;22(6):757-765.e3. doi:10.1016/j.chom.2017.10.020.
1.
Ogino S, Nowak JA, Hamada T, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018;67(6):1168-1180. doi:10.1136/gutjnl-2017-315537.